Tirzepatide associated with greater weight loss in women than men

Women lost up to 24.6% of their body weight with tirzepatide compared with 18.1% in men

2024-09-11

(Press-News.org) All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced greater weight loss, according to new post hoc research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

The post hoc analysis, which included the four SURMOUNT trials [1], compared tirzepatide with a placebo for up to 72 to 88 weeks in 4,677 adults (2,999 females, 1,678 males) living with obesity, highlighting potential sex differences in the response.

Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has consistently shown robust body weight reduction in adults with obesity and overweight, with or without type 2 diabetes in the SURMOUNT trials.

The phase 3 SURMOUNT clinical trials examined the efficacy and safety of tirzepatide versus placebo in people with a BMI of 30 kg/m² and above, or 27 kg/m² with at least one weight-related comorbidity without type 2 diabetes (SURMOUNT-1, 72 weeks), with type 2 diabetes (T2D) (SURMOUNT-2; 72 weeks), and without T2D after a 12-week intensive lifestyle intervention (SURMOUNT-3; 72 weeks from randomisation), or after an 88 week intervention (SURMOUNT-4; 36-week open label tirzepatide lead-in and 52 weeks following randomisation).

The post-hoc analyses examined whether the weight-lowering effects of tirzepatide vary according to sex in these trials. All randomised participants (51-71% female) who received at least one dose of the study drug (tirzepatide 5, 10, or 15 mg, or placebo) were included.

At randomisation, average body weight and body mass index (BMI) for females vs males was 99.8 vs 115.2 kg and 38.2 vs 37.6 kg/m2 in SURMOUNT-1; 94.8 vs 106.8 kg and 36.7 vs 35.4 kg/m2 in SURMOUNT-2; 95.4 vs 112.9 kg and 35.8 vs 36.1 kg/m2 in SURMOUNT-3; and 79.6 vs 98.6 kg and 30.1 vs 31.4 kg/m2 in SURMOUNT-4, respectively.

The researchers examined the average percentage change in body weight from randomisation to week 72 (SURMOUNT-1, -2, and -3) or to week 52 (SURMOUNT-4) by sex, as well as assessing the sex differences in the proportion of participants achieving weight reduction targets of at least 5%, 10%, and 15%.

The analyses found that across all trials, tirzepatide treatment was associated with significant weight reduction compared to placebo, regardless of sex—ranging from -11.5% to -27.6% in females and -8.8% to -18.9% in males.

Additionally, the odds of achieving weight reduction targets were significantly higher with tirzepatide treatment compared with placebo in both males and females.

Nevertheless, female participants achieved greater reductions in weight with tirzepatide treatment (up to 24.6%) compared to male participants (up to 18.1%) across all trials.

Similar proportions of males and females achieved the body weight reduction thresholds of at least 5%, 10%, and 15% with tirzepatide treatment in SURMOUNT-1, -2, and -4, or achieved the 15% target in SURMOUNT-3.

However, in the SURMOUNT 3 trial involving adults without T2D, tirzepatide-treated females were significantly more likely to achieve a body weight reduction of at least 5% and 10% than tirzepatide-treated males.

The safety profile was broadly similar by sex, but a numerically higher incidence of nausea and vomiting was noted in females.“This post hoc analysis underscores the consistent benefits of tirzepatide for women and men. More research is needed to understand the mechanism by which females may experience more weight reduction in these trials,” said lead author Dr Luis-Emilio García from Eli Lilly and Company, Indianapolis, USA.

END

ELSE PRESS RELEASES FROM THIS DATE:

Rapid control of blood sugar levels in women with gestational diabetes can reverse the risk of their children developing obesity, US study finds

2024-09-11

Swiftly achieving glycaemic control after a diagnosis of gestational diabetes can bring the baby’s risk obesity in childhood down to a level similar to that of children whose mothers did not have gestational diabetes, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), has found. Gestational diabetes, a type of diabetes that can develop during pregnancy, affects 14% of pregnant women globally and is becoming more common, with those who are living with obesity, have a family ...

Semaglutide’s cardiovascular benefits are maintained in people with impaired kidney function

2024-09-11

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don’t have diabetes, whether or not they also have impaired kidney function, according to new research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept). The results are based on a pre-specified analysis of the SELECT trial which found that adults with overweight or obesity but not diabetes taking semaglutide for more than 3 years had a 20% lower risk of MACE or ...

Study reveals key predictors for achieving and sustaining blood glucose control and weight loss with tirzepatide in adults with type 2 diabetes

2024-09-11

The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a long-acting insulin) for type 2 diabetes (T2D) [1]. Now new research examining a broad range of potential predictors of sustaining blood sugar control and weight loss indicates that greater weight loss, better β-cell function, and a greater decrease in low-density lipoprotein cholesterol (LDL-C or “bad cholesterol”) during the first year of tirzepatide therapy are the most ...

Avian flu found in wastewater of 10 Texas cities through virome sequencing by researchers at UTHealth Houston and Baylor College of Medicine

2024-09-11

Avian influenza A(H5N1) virus, which spread to cattle and infected 14 people this year, was detected using virome sequencing in the wastewater of 10 Texas cities by researchers at UTHealth Houston and Baylor College of Medicine. The virome is the collection of viruses in a sample, in this case a wastewater sample. The information was published in the New England Journal of Medicine. Until March 2024, H5N1 had not been detected in 1,337 wastewater samples analyzed by the team. But from March 4 to July 15 (the end of data collection for this article), H5N1 was ...

Culturing muscle cells

2024-09-11

Harvard stem cell biologists have pioneered a groundbreaking 3D organoid culture method for generating large numbers of adult skeletal muscle satellite cells, also known as muscle stem cells, in vitro. The ability to efficiently make functional muscle stem cells in this way is expected to accelerate understanding of and treatments for disorders of skeletal muscle, including those that are neuromuscular in origin. The new technique, detailed in Nature Biotechnology, also provides a powerful tool for studying muscle biology. "People will be able to do all these engraftment and regeneration experiments because suddenly, you have millions of cells,” said co-author and Harvard research ...

ORNL debuts convergent manufacturing platform at IMTS 2024

2024-09-11

A new convergent manufacturing platform, developed in only five months at the Department of Energy’s Oak Ridge National Laboratory, is debuting at the International Manufacturing Technology Show, or IMTS, in Chicago, Sept. 9–12, 2024. The technology, called Future Foundries, opens the door for hundreds of thousands of small- and medium-sized companies to join the convergent manufacturing revolution, according to ORNL researchers. It is a cutting-edge platform that integrates multiple advanced manufacturing systems into a single, agile platform. “The democratization ...

New insights could help prevent psychosis relapses in youth and young adults

2024-09-11

New findings from McGill University researchers could help clinicians understand the course of delusions in youth and young adults that signal the need for a timely intervention to prevent a full relapse of psychosis. Delusions — strong beliefs that don't align with commonly accepted reality— are a defining symptom of psychosis but are not sufficiently understood. For the first time, researchers studied whether delusion themes, such as paranoia or grandiosity, stay the same or shift between psychotic episodes in youth and young adults undergoing early intervention treatment. The importance of timely ...

Biogeochemistry scientists from around the world, led by the ASC's Margenot, publish position paper on tackling “hidden” phosphorus

2024-09-11

As the world tries to mitigate agriculture’s effect on the environment, much of the story can be found in the soils, which stores and cycles nutrient elements of carbon, nitrogen, and phosphorus. Biogeochemistssuch as Andrew Margenot, Associate Director of the Agroecosystem Sustainability Center, are set to find answers, but for Margenot and other biogeochemistry experts who specialize in studying phosphorus cycling, the challenge is first being able to accurately measure where phosphorus has accumulated in the <100 years since humans began to increase ...

New, rare type of small cell lung cancer identified by MSK research team

2024-09-11

A team of doctors and researchers at Memorial Sloan Kettering Cancer Center (MSK) have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Their findings, which include a detailed analysis of the clinical and genetic features of the disease, also highlight vulnerabilities that could help doctors make better treatment decisions for people diagnosed with it. “It’s not every day you identify a new subtype of cancer,” says Natasha Rekhtman, MD, PhD, an MSK pathologist specializing in lung cancer and the first author of a paper published August 26 in Cancer Discovery presenting ...

Light pollution a new Alzheimer’s risk factor

2024-09-11

Outdoor light at night could be a significant risk factor in Alzheimer’s disease, according to new research from Rush. While light pollution is associated with increased risk of some disorders and diseases, this is the first time it had been associated with Alzheimer’s disease. The study was conducted at Rush University System for Health and published in Frontiers in Neuroscience. “Our research shows that there is an association in the U.S. between Alzheimer’s disease prevalence and exposure to light at night, particularly in those under the age of 65,” said lead investigator, Robin Voigt-Zuwala, PhD, an associate professor at Rush. “Nightly ...

Tirzepatide associated with greater weight loss in women than men

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: